AI Science Tracker
EN

Department of Nuclear Medicine, Qilu Hospital of Shandong University, No. 107, Cultural West Road, Jinan, 250012 China.

1 discovery from 2023

Discoveries

Performance of 18 F-DCFPyL PET/CT in Primary Prostate Cancer Diagnosis, Gleason Grading and D'Amico Classification: A Radiomics-Based Study.

Source check: Source checked. Not independent scientific confirmation.

Finding: A three-layer ensemble of PET/CT radiomic features was evaluated against pathology in 138 treatment-naive patients and reported specific malignancy and risk-classification results; evidence is retrospective, monocentric and internally resampled only. AI role: PET/CT radiomics ensemble for pathology-referenced classification. The article appeared in Phenomics (Cham, Switzerland).

Technology: PET/CT radiomics ensemble for pathology-referenced classification

Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.

AI contribution
PET/CT radiomics ensemble for pathology-referenced classification
Test and result
A three-layer ensemble of PET/CT radiomic features was evaluated against pathology in 138 treatment-naive patients and reported specific malignancy and risk-classification results; evidence is retrospective, monocentric and internally resampled only.
Limitation / still unknown
The result is limited to the described dataset, cohort, experimental system, or validation design; generalization beyond that scope and downstream real-world benefit are not established. Author affiliation was not stated in the reviewed abstract or metadata.
Evidence sources and annotation context

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

Evidence sources: https://pmc.ncbi.nlm.nih.gov/articles/PMC10781655/?report=xml · https://pubmed.ncbi.nlm.nih.gov/38223686/

Source checked · editorial details

The source page was checked against this entry. Independent confirmation is not assessed by this label.

Source type: paper. Paper: linked separately.

Review date: 22 Nov 2026. Review scope: Primary result-bearing material for the stated method, result and evaluation, with bibliographic version information..

No follow-up recorded; this is not a claim that no follow-up exists. Follow-up review scope and date are not recorded. No source-supported relationships recorded.

Editorial assessment: Impact 2/5 · Validation 2/5 · Novelty 2/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Open the interactive profile for the timeline, or browse all organizations and model families.